Origimm (Origins of Immunity) is a young innovative Austrian biotechnology company, which specializes in discovery of antigens and functional drug targets for the prevention and treatment of infectious diseases and dermatological conditions associated with various microbial species.

The company uses its proprietary ProVaDis technology to identify highly protective antigens by reverse functional screening and significantly improves success in the selection of the most protective antigen candidates. Origimm’s lead program is a vaccine against Propionibacterium acnes (P. acnes) to prevent and treat acne vulgaris and to prevent implant-associated P. acnes infections.

Relying on the power of scientific rigor and honesty, Origimm strives to establish itself as the leader in nonconventional, breakthrough medical research that delivers superior treatment solutions.